To study the effect of dipyridamole on mortality after stroke.
- Dipyridamole (Persantine®)Drug
Intervention Desc: Platelet aggregation inhibitor
Controlled, stratified, randomized, double-blind study of 169 patients. Patients were stratified according to sex, age, presence of hypertension, clinical diagnosis and time between ischemic event and commencement of treatment.
Patients were randomized to receive 400 mg dipyridamole in four daily doses, initially, or placebo. These patients were evaluated after having received therapy for an average of 14 months. Patients who received less than 6 months of therapy were excluded. The dose of dipyridamole was then doubled and the trial continued for a mean period of 11 months. Patients who had taken the high dose for less than 9 months were excluded. The patients were seen monthly for the first few months and every 3 months thereafter.
|Type||Measure||Time Frame||Safety Issue|